LT3057962T - Hidrochlorido druskos forma, skirta ezh2 inhibavimui - Google Patents
Hidrochlorido druskos forma, skirta ezh2 inhibavimuiInfo
- Publication number
- LT3057962T LT3057962T LTEPPCT/US2014/060724T LTUS2014060724T LT3057962T LT 3057962 T LT3057962 T LT 3057962T LT US2014060724 T LTUS2014060724 T LT US2014060724T LT 3057962 T LT3057962 T LT 3057962T
- Authority
- LT
- Lithuania
- Prior art keywords
- salt form
- hydrochloride salt
- ezh2 inhibition
- ezh2
- inhibition
- Prior art date
Links
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 title 1
- 101150090105 Ezh2 gene Proteins 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361891786P | 2013-10-16 | 2013-10-16 | |
| PCT/US2014/060724 WO2015057859A1 (en) | 2013-10-16 | 2014-10-15 | Hydrochloride salt form for ezh2 inhibition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3057962T true LT3057962T (lt) | 2023-12-11 |
Family
ID=52828660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/US2014/060724T LT3057962T (lt) | 2013-10-16 | 2014-10-15 | Hidrochlorido druskos forma, skirta ezh2 inhibavimui |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10040782B2 (lt) |
| EP (2) | EP4324525A3 (lt) |
| JP (2) | JP6608812B2 (lt) |
| KR (1) | KR102142177B1 (lt) |
| CN (1) | CN105829302B (lt) |
| AU (2) | AU2014337300B2 (lt) |
| CA (1) | CA2925889C (lt) |
| CL (1) | CL2016000866A1 (lt) |
| DK (1) | DK3057962T3 (lt) |
| EA (1) | EA038869B1 (lt) |
| ES (1) | ES2960953T3 (lt) |
| FI (1) | FI3057962T3 (lt) |
| HU (1) | HUE063984T2 (lt) |
| IL (1) | IL244787B (lt) |
| LT (1) | LT3057962T (lt) |
| MA (1) | MA38949A1 (lt) |
| MX (1) | MX2016004703A (lt) |
| MY (1) | MY179802A (lt) |
| PE (1) | PE20161273A1 (lt) |
| PL (1) | PL3057962T3 (lt) |
| PT (1) | PT3057962T (lt) |
| SG (2) | SG11201602269QA (lt) |
| SI (1) | SI3057962T1 (lt) |
| WO (1) | WO2015057859A1 (lt) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2745016T3 (es) | 2012-04-13 | 2020-02-27 | Epizyme Inc | Bromhidrato de N-((4,6-dimetil-2-oxo-L,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H-piran-4-il)amino)-4-metil-4'-(morfolinometil)-[L,1'-bifenil]-3-carboxamida para su uso en el tratamiento de un trastorno proliferativo celular del sistema hematológico |
| HUE063984T2 (hu) | 2013-10-16 | 2024-02-28 | Epizyme Inc | Hidroklorid só forma az EZH2 gátlásához |
| BR112016012713A2 (pt) | 2013-12-06 | 2017-08-08 | Epizyme Inc | Método para tratamento de câncer em um paciente necessitado, e, método de selecionar um paciente para um método de tratamento |
| SG10201811128RA (en) | 2014-06-17 | 2019-01-30 | Epizyme Inc | Ezh2 inhibitors for treating lymphoma |
| IL289947B2 (en) | 2014-10-16 | 2024-06-01 | Epizyme Inc | A method for treating cancer |
| PL3220916T3 (pl) | 2014-11-17 | 2023-08-14 | Epizyme, Inc. | Sposób leczenia raka n-((4,6-dimetylo-2-okso-1,2-dihydropirydyn-3-ylo)metylo)-5-(etylo(tetrahydro-2h-piran-4-ylo)amino)-4-metylo-4'-(morfolinometylo)-[1,1'-bifenylo]-3-karboksyamidem |
| SG11201708286PA (en) | 2015-04-20 | 2017-11-29 | Epizyme Inc | Combination therapy for treating cancer |
| WO2016201328A1 (en) | 2015-06-10 | 2016-12-15 | Epizyme, Inc. | Ezh2 inhibitors for treating lymphoma |
| WO2017035234A1 (en) | 2015-08-24 | 2017-03-02 | Epizyme, Inc. | Method for treating cancer |
| AU2017211331A1 (en) | 2016-01-29 | 2018-06-07 | Epizyme, Inc. | Combination therapy for treating cancer |
| CA3025933A1 (en) | 2016-06-01 | 2017-12-07 | Epizyme, Inc. | Use of ezh2 inhibitors for treating cancer |
| EP3471830A4 (en) | 2016-06-17 | 2020-02-26 | Epizyme Inc | EZH2 INHIBITORS TO TREAT CANCER |
| JP7125353B2 (ja) | 2017-01-19 | 2022-08-24 | 第一三共株式会社 | Ｈｔｌｖ－１関連脊髄症を治療することに用いるための医薬組成物 |
| WO2018183885A1 (en) | 2017-03-31 | 2018-10-04 | Epizyme, Inc. | Combination therapy for treating cancer |
| JP2020522687A (ja) | 2017-06-02 | 2020-07-30 | エピザイム，インコーポレイティド | 癌を処置するためのｅｚｈ２阻害剤の使用 |
| CA3074720A1 (en) | 2017-09-05 | 2019-03-14 | Epizyme, Inc. | Combination therapy for treating cancer |
| WO2020011607A1 (en) | 2018-07-09 | 2020-01-16 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
| JP2022545467A (ja) | 2019-08-22 | 2022-10-27 | ジュノー セラピューティクス インコーポレイテッド | Ｔ細胞療法とｚｅｓｔｅホモログ２エンハンサー（ＥＺＨ２）阻害剤との併用療法および関連方法 |
| AU2023262308A1 (en) | 2022-04-27 | 2024-10-03 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0733729A (ja) | 1993-07-26 | 1995-02-03 | Kirin Brewery Co Ltd | Ｎ−シアノ−ｎ′−置換−アリールカルボキシイミダミド化合物の製造法 |
| HUT74450A (en) | 1993-12-27 | 1996-12-30 | Eisai Co Ltd | Anthranilic acid derivative and pharmaceutical compns. contg. such compds. |
| DE19516776A1 (de) | 1995-05-10 | 1996-11-14 | Boehringer Ingelheim Int | Chromatin-Regulatorgene |
| US5741819A (en) | 1995-06-07 | 1998-04-21 | 3-Dimensional Pharmaceuticals, Inc. | Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors |
| JP3906935B2 (ja) | 1995-12-18 | 2007-04-18 | 杏林製薬株式会社 | Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
| AU6060099A (en) | 1998-09-30 | 2000-04-17 | Procter & Gamble Company, The | 2-substituted ketoamides |
| UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
| ATE438624T1 (de) | 2000-12-28 | 2009-08-15 | Shionogi & Co | 2-pyridonderivate mit affinität für den cannabinoid-typ-2-rezeptor |
| US7700293B2 (en) | 2001-08-02 | 2010-04-20 | The Regents Of The University Of Michigan | Expression profile of prostate cancer |
| EP2130820A1 (en) | 2002-02-19 | 2009-12-09 | Shionogi & Co., Ltd. | Antipruritics |
| TW200306155A (en) | 2002-03-19 | 2003-11-16 | Du Pont | Benzamides and advantageous compositions thereof for use as fungicides |
| US7442685B2 (en) | 2003-06-13 | 2008-10-28 | The University Of North Carolina At Chapel Hill | DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia |
| EP1765994B1 (en) | 2004-06-01 | 2009-11-18 | The University of North Carolina at Chapel Hill | Reconstituted histone methyltransferase complex and methods of identifying modulators thereof |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| DE602006019423D1 (de) | 2005-06-02 | 2011-02-17 | Univ North Carolina | Reinigung, charakterisierung und wiederherstellung einer ubiquitin-e3-ligase |
| FR2889526B1 (fr) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| KR101347102B1 (ko) | 2005-10-19 | 2014-01-03 | 그뤼넨탈 게엠베하 | 신규한 바닐로이드 수용체 리간드 및 약제를 제조하기 위한이의 용도 |
| AU2006306541B2 (en) | 2005-10-21 | 2011-07-14 | Merck Sharp & Dohme Corp. | Potassium channel inhibitors |
| ATE547514T1 (de) | 2005-10-28 | 2012-03-15 | Univ North Carolina | Protein-demethylasen mit einer jmjc-domäne |
| WO2007070818A1 (en) | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| EP1974055A4 (en) | 2006-01-20 | 2010-01-27 | Univ North Carolina | DIAGNOSTIC AND THERAPEUTIC OBJECTIVES AGAINST LEUKEMIA |
| AU2007333021A1 (en) | 2006-05-15 | 2008-06-19 | Irm Llc | Terephthalamate compounds and compositions, and their use as HIV integrase inhibitors |
| WO2007136592A2 (en) | 2006-05-18 | 2007-11-29 | Amphora Discovery Corporation | 2-0x0-l,2-dihydr0quin0line derivatives, compositions, and uses thereof as antiproliferative agents |
| EP2086318A4 (en) | 2006-10-10 | 2009-12-23 | Burnham Inst Medical Research | NEUROPROTEKTIVE COMPOSITIONS AND METHOD |
| US8314087B2 (en) | 2007-02-16 | 2012-11-20 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and methods of use |
| US8338437B2 (en) | 2007-02-28 | 2012-12-25 | Methylgene Inc. | Amines as small molecule inhibitors |
| WO2008113006A1 (en) | 2007-03-14 | 2008-09-18 | Xenon Pharmaceuticals Inc. | Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions |
| DE102007017884A1 (de) | 2007-04-13 | 2008-10-16 | Grünethal GmbH | Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
| US20090012031A1 (en) | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | EZH2 Cancer Markers |
| JP2011502148A (ja) | 2007-10-31 | 2011-01-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 疼痛の治療用としてのｐ２ｘ３受容体アンタゴニスト |
| AU2008337286B2 (en) | 2007-12-19 | 2014-08-07 | Cancer Research Technology Limited | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
| WO2009124137A2 (en) | 2008-04-01 | 2009-10-08 | Mount Sinai School Of Medicine Of New York University | Method of suppressing gene transcription through histone lysine methylation |
| US20100113415A1 (en) | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
| CA2730064A1 (en) | 2008-08-08 | 2010-02-11 | Asim Kumar Debnath | Small molecule inhibitors of retroviral assembly and maturation |
| FR2934995B1 (fr) | 2008-08-14 | 2010-08-27 | Sanofi Aventis | Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique |
| WO2010111653A2 (en) | 2009-03-27 | 2010-09-30 | The Uab Research Foundation | Modulating ires-mediated translation |
| WO2011011366A2 (en) | 2009-07-20 | 2011-01-27 | Constellation Pharmaceuticals | Agents for stimulating activity of methyl modifying enzymes and methods of use thereof |
| US8329149B2 (en) | 2009-12-30 | 2012-12-11 | Avon Products, Inc. | Topical lightening composition and uses thereof |
| PT2566327T (pt) | 2010-05-07 | 2017-05-26 | Glaxosmithkline Llc | Indoles |
| ES2534804T3 (es) | 2010-05-07 | 2015-04-28 | Glaxosmithkline Llc | Indazoles |
| WO2012005805A1 (en) | 2010-05-07 | 2012-01-12 | Glaxosmithkline Llc | Azaindazoles |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| RU2765155C2 (ru) | 2010-09-10 | 2022-01-26 | Эпизайм, Инк. | Ингибиторы ezh2 человека и способы их применения |
| WO2012068589A2 (en) | 2010-11-19 | 2012-05-24 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| JP5908493B2 (ja) | 2010-12-01 | 2016-04-26 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | インドール |
| AU2011336272A1 (en) | 2010-12-03 | 2013-06-20 | Epizyme, Inc. | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof |
| WO2012118812A2 (en) | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| ES2718900T3 (es) | 2012-03-12 | 2019-07-05 | Epizyme Inc | Inhibidores de EZH2 humana y métodos de uso de los mismos |
| ES2745016T3 (es) | 2012-04-13 | 2020-02-27 | Epizyme Inc | Bromhidrato de N-((4,6-dimetil-2-oxo-L,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H-piran-4-il)amino)-4-metil-4'-(morfolinometil)-[L,1'-bifenil]-3-carboxamida para su uso en el tratamiento de un trastorno proliferativo celular del sistema hematológico |
| JP6340361B2 (ja) | 2012-04-13 | 2018-06-06 | エピザイム，インコーポレイティド | がんを処置するための組合せ治療 |
| WO2013173441A2 (en) | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| PT2908823T (pt) | 2012-10-15 | 2019-11-04 | Epizyme Inc | Métodos para tratamento do cancro |
| BR112015008487B1 (pt) | 2012-10-15 | 2022-05-31 | Epizyme, Inc | Compostos de benzeno substituído, composição farmacêutica compreendendo os ditos compostos e uso terapêutico dos mesmos para tratar um distúrbio mediado por ezh2 |
| EP2935214B1 (en) | 2012-12-21 | 2019-02-20 | Epizyme, Inc. | 1,4-pyridone compounds |
| WO2014100665A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
| CA2903572A1 (en) | 2013-03-15 | 2014-10-23 | Epizyme, Inc. | Substituted benzene compounds |
| US9776996B2 (en) | 2013-03-15 | 2017-10-03 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| US9624205B2 (en) | 2013-07-19 | 2017-04-18 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| EP3022184B1 (en) | 2013-07-19 | 2017-09-27 | Epizyme, Inc. | Substituted benzene compounds |
| HUE063984T2 (hu) | 2013-10-16 | 2024-02-28 | Epizyme Inc | Hidroklorid só forma az EZH2 gátlásához |
-
2014
- 2014-10-15 HU HUE14854272A patent/HUE063984T2/hu unknown
- 2014-10-15 EP EP23203529.5A patent/EP4324525A3/en active Pending
- 2014-10-15 LT LTEPPCT/US2014/060724T patent/LT3057962T/lt unknown
- 2014-10-15 CA CA2925889A patent/CA2925889C/en active Active
- 2014-10-15 MA MA38949A patent/MA38949A1/fr unknown
- 2014-10-15 MY MYPI2016000542A patent/MY179802A/en unknown
- 2014-10-15 FI FIEP14854272.3T patent/FI3057962T3/fi active
- 2014-10-15 JP JP2016519378A patent/JP6608812B2/ja active Active
- 2014-10-15 US US15/029,848 patent/US10040782B2/en active Active
- 2014-10-15 SI SI201432051T patent/SI3057962T1/sl unknown
- 2014-10-15 CN CN201480056428.6A patent/CN105829302B/zh active Active
- 2014-10-15 MX MX2016004703A patent/MX2016004703A/es active IP Right Grant
- 2014-10-15 PL PL14854272.3T patent/PL3057962T3/pl unknown
- 2014-10-15 KR KR1020167011534A patent/KR102142177B1/ko active IP Right Grant
- 2014-10-15 DK DK14854272.3T patent/DK3057962T3/da active
- 2014-10-15 SG SG11201602269QA patent/SG11201602269QA/en unknown
- 2014-10-15 SG SG10201901977XA patent/SG10201901977XA/en unknown
- 2014-10-15 EA EA201690650A patent/EA038869B1/ru unknown
- 2014-10-15 EP EP14854272.3A patent/EP3057962B1/en active Active
- 2014-10-15 WO PCT/US2014/060724 patent/WO2015057859A1/en active Application Filing
- 2014-10-15 PT PT148542723T patent/PT3057962T/pt unknown
- 2014-10-15 PE PE2016000506A patent/PE20161273A1/es unknown
- 2014-10-15 ES ES14854272T patent/ES2960953T3/es active Active
- 2014-10-15 AU AU2014337300A patent/AU2014337300B2/en active Active
-
2016
- 2016-03-28 IL IL244787A patent/IL244787B/en unknown
- 2016-04-13 CL CL2016000866A patent/CL2016000866A1/es unknown
-
2018
- 2018-06-05 US US16/000,539 patent/US10710987B2/en active Active
- 2018-12-11 JP JP2018231817A patent/JP2019052181A/ja active Pending
-
2019
- 2019-04-02 AU AU2019202246A patent/AU2019202246A1/en not_active Abandoned
-
2020
- 2020-06-03 US US16/891,427 patent/US20210017163A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL244787A0 (en) | Hydrochloride salt form for ezh2 inhibition | |
| PL3628670T3 (pl) | Postać soli dla inhibicji ezh2 | |
| HK1224298A1 (zh) | 晶體溴結構域抑制劑 | |
| HK1220459A1 (zh) | 激酶抑制劑 | |
| HK1214813A1 (zh) | 激酶抑制劑 | |
| HK1222387A1 (zh) | 作為 抑制劑的芳基吡咯並吡啶衍生的化合物 | |
| HK1211578A1 (en) | Amidoimidazopyridazines as mknk-1 kinase inhibitors mknk-1 | |
| HK1219104A1 (zh) | 激酶抑制劑 | |
| HK1216531A1 (zh) | 新的抑制劑 | |
| EP3007689A4 (en) | NON-SELECTIVE KINASE INHIBITORS | |
| EP2968358A4 (en) | NOVEL CHOLINKINASE INHIBITORS | |
| ZA201506296B (en) | 2-acylaminothiazole derivative or salt thereof | |
| HK1232227A1 (zh) | 作為 抑制劑的喹嗪酮衍生物 | |
| IL245737B (en) | Glucosylceramide synthase inhibitors | |
| PT2900066T (pt) | Método e sistema para o aumento da eficácia biocida de sais de monoalquilditiodiocarbamatos | |
| GB201307155D0 (en) | Kinase inhibitors |